This area is reserved for registered users. Please register or login.

Stelara Receives Approval for Treatment of Moderately to Severely Active Crohn’s Disease

Janssen is pleased to announce that Stelara (ustekinumab) has received European approval for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist or have contraindications to such therapies.   Stelara, a human monoclonal antibody, is the first biologic therapy for Crohn’s disease that targets interleukin (IL)-12 and IL-23 cytokines. It also approved for the treatment of psoriasis and psoriatic arthritis. Abnormal regulation of IL-12 and IL-23 has been associated with immune mediated diseases,…